We have long been engaged in the development of peptide radioligands for cancer theranostics, with a great part of our activities being focused on gastrin-releasing peptide receptor (GRPR)-directed analogs for diagnosis/treatment of human prostate cancer [7,9,26]. The gene discussed is GRPR; the disease is prostate carcinoma.